Myasthenia Gravis Treatments (gMG)

Insights from Veeva Projected Prescription and Procedure Data: Commercial Momentum and Market Adoption

Powered by Compass Prescriber and National, this report shows estimated unique patient starts and healthcare providers (HCPs) for products treating Myasthenia Gravis, as well as those products' other on-label conditions.

Compass includes non-retail channels, offering a more complete picture of commercial momentum for the gMG market, where there is a mix of in-office infusions and self-administrations. The performance metrics below represent cumulative, 2026 year-to-date totals through September.

Brand	Manufacturer	Disease Area	YTD Patient Starts	YTD HCP Counts
Imaavy	Janssen	Myasthenia Gravis	1,107	415
		Acquired Hemolytic Anemias	4	4
Rystiggo	UCB	Myasthenia Gravis	748	403
Soliris	AstraZeneca	Myasthenia Gravis	433	356
		Atypical Hemolytic Uremic Syndrome	268	402
		Neuromyelitis Optica Spectrum Disorder	100	104
		Paroxysmal Nocturnal Hemoglobinuria	69	135
Ultomiris	AstraZeneca	Myasthenia Gravis	2,087	1,132
		Atypical Hemolytic Uremic Syndrome	809	843
		Paroxysmal Nocturnal Hemoglobinuria	482	693
		Neuromyelitis Optica Spectrum Disorder	468	347
Uplizna	Amgen	Myasthenia Gravis	853	259
		Neuromyelitis Optica Spectrum Disorder	812	386
		Immunoglobulin G4-related Disease	733	322
Vyvgart	Argenx	Myasthenia Gravis	3,138	1,655
Vyvgart Hytrulo	Argenx	Myasthenia Gravis	2,242	1,227
		Polyneuropathies / Peripheral Neuropathy	2,335	1,069
Zilbrysq	UCB	Myasthenia Gravis	480	141

Data through September 30, 2026

Additional recent launches also available:

- **Arynta** (Azurity)
- **Avlayah** (Denali Therapeutics)
- **Awiqli** (Novo Nordisk)
- **Bixlenvo** (Gilead Sciences)
- **Favlyxa** (Avyxa Pharma)
- **Hepcludex** (Gilead Sciences)
- **Lipfendra** (Merck)
- **mFLUSIVA** (Moderna)
- **Rasonque** (Revolution Medicines)
- **Xocova** (Shionogi)
- **Zenbexus** (Bristol Myers Squibb)

© 2027 Veeva Systems Inc. All rights reserved. Veeva, V, Vault and Crossix are registered trademarks of Veeva Systems Inc. Veeva Systems owns other registered and unregistered trademarks. Other names used herein may be trademarks of their respective owners. Veeva Compass Prescriber & Compass National are syndicated data products that leverage two patented projection methodologies to estimate prescription, procedure, and patient volume within the United States. Centers for Medicare & Medicaid Services (CMS) drug utilization data is accessed through Virtual Research Data Center (VRDC), and leveraged as part of these methodologies. These estimates are fully refreshed on a weekly and monthly basis.

To learn more about these launch brands or explore custom market analysis, contact: **anthony.billinger@veeva.com**